Enhanced Strategic Partnership Between Citeline and Recursion: Revolutionizing Healthcare Outcomes Through Data-Driven Collaboration
Citeline, a prominent provider of clinical solutions for the life sciences industry, has announced an enhanced strategic partnership with Recursion, a leading tech-bio company specializing in decoding biology through advanced data science and automation. Recursion's comprehensive platform integrates proprietary multimodal datasets, AI models, and experimental biology to streamline the discovery and development process. By incorporating Citeline's real-world data and evidence capabilities, Recursion aims to enhance trial design, site selection, and development decision-making for more efficient and informed outcomes.
Fred Hassan, Norstella Executive Chair, expressed pride in the collaboration with Recursion, highlighting the positive impact of Citeline's real-world data on the tech-bio company's programs. The integration of Citeline SmartSolutions into Recursion's platform is expected to provide clarity and foresight from the early stages of development, contributing to more effective decision-making and progress.
Recursion's CEO and President, Najat Khan, emphasized the significance of Citeline's data and evidence capabilities in supporting the company's pipeline, particularly in contextualizing data from the REC-4881 Phase I/II study. The investment in Recursion's ClinTech platform has already shown promising results, with notable improvements in enrollment rates, showcasing the value of an integrated approach to data-driven decision-making.
This expanded partnership underscores a shared commitment to fostering a predictive, interconnected, and patient-centric biopharmaceutical ecosystem. By leveraging insights from real-world data throughout the discovery and clinical development process, the collaboration aims to accelerate the journey from pipeline to patient, ultimately benefiting healthcare outcomes and patient care.
For more information on Citeline and its offerings, visit Citeline.com.
Citeline, a subsidiary of Norstella, provides a range of business intelligence solutions tailored to the needs of life science professionals. With a focus on connecting treatments to patients and vice versa, Citeline's offerings support clinical, commercial, and regulatory decision-making by delivering and analyzing data to drive growth opportunities. The company's global teams of experts cover key areas in the pharmaceutical, biomedical, and medtech industries, offering insights on diseases, clinical trials, drug R&D, market forecasts, and more.
Recursion, a clinical-stage TechBio company listed on NASDAQ under the symbol RXRX, is dedicated to decoding biology to revolutionize healthcare outcomes. Through its innovative drug discovery and development platform, Recursion OS, the company is advancing a diverse portfolio of investigational medicines in oncology, rare diseases, neuroscience, immunology, and other therapeutic areas with unmet needs. Powered by proprietary data and AI models, Recursion OS aims to accelerate the translation of complex science into impactful medicines for patients in need.
For media inquiries related to Citeline, please contact Diffusion PR at [email protected] or call (213) 318-4500. For media and investor inquiries regarding Recursion, reach out to [email protected] and [email protected], respectively.